NY-SECURITYSCORECARD
20.9.2022 02:25:16 CEST | Business Wire | Press release
SecurityScorecard, the global leader in cybersecurity ratings, today announced it has launched a series of resources designed to help organizations navigate increased scrutiny of budgets and ensure that security efforts get the funding needed to support the business.
The content and tools will make it easier for organizations to realize and demonstrate the return on their security program.
Economic uncertainty is affecting organizations across industries. While expenditures are being scrutinized, cybersecurity budgets are no exception, and bad actors often take advantage of these turbulent times. Therefore It's more important than ever for security leaders to articulate the value of their security and vendor risk management programs and effectively communicate clear ROI for technology investments.
The resources include the ebook 5 Ways to Secure Your Organization In Turbulent Times, and SecurityScorecard's Return on Investment (ROI) Calculator, a free high-level estimate of the Total Economic Impact of SecurityScorecard. The Interactive calculator will help organizations understand the Total Economic Impact of SecurityScorecard's holistic security rating platform.
The SecurityScorecard calculator is based upon the Forrester Consulting study, The Total Economic Impact of SecurityScorecard, commissioned by SecurityScorecard. Working with SecurityScorecard customers, Forrester identified and quantified key benefits of investing in SecurityScorecard's integrated approach to managing cybersecurity risk, including:
- Increased efficiency in risk management
- Technology efficiencies and consolidation
- Improved security posture
“Organizations around the world are facing challenging financial climates, putting enormous pressure on CISOs to communicate value to their boards and leaders,” said Aleksandr Yampolskiy, CEO and co-Founder, SecurityScorecard. “Threat actors take advantage of turbulent times when staffing and resources tighten. The faster your team can prove value and justify your investments, the faster you can address your most critical issues.”
In addition to the ROI calculator, SecurityScorecard is also helping organizations improve the ROI of their security programs by giving them the ability to:
- Achieve faster time to value by automating cybersecurity processes
- Quantify risk in financial terms to the board and test different scenarios of potential impacts
- Develop key metrics that the board cares about for defining, understanding, and quantifying cybersecurity threats
- Set automated alerts and rules to prevent missed issues within the organization and any of its third-party vendors.
SecurityScorecard is also hosting a four-part, global webinar series to inform viewers about the key areas that leading security teams are prioritizing to proactively secure their organizations. The webinar series, which kicks off September 29th, will have dedicated sessions for North America, APAC and EMEA viewers and cover topics including:
- Taking Control of Your Security in Turbulent Times
- Carve Through the Noise by Prioritizing the Most Critical Threats
- Show the Value of your Security Program
- Showcase your Strong Security Posture to be the Vendor of Choice
Visit here to register for each webinar and learn more about how SecurityScorecard is helping organizations ensure double the return on investment on security awareness and prevention, hold vendors accountable, prioritize further areas of investment, and calculate your ROI estimate.
About SecurityScorecard
Funded by world-class investors including Evolution Equity Partners, Silver Lake Waterman, Sequoia Capital, GV, Riverwood Capital, and others, SecurityScorecard is the global leader in cybersecurity ratings with more than 12 million companies continuously rated. Founded in 2013 by security and risk experts Dr. Aleksandr Yampolskiy and Sam Kassoumeh, SecurityScorecard's patented rating technology is used by over 30,000 organizations for enterprise risk management, third-party risk management, board reporting, due diligence, cyber insurance underwriting, and regulatory oversight. SecurityScorecard is the first cybersecurity ratings company to offer digital forensics and incident response services, providing a 360-degree approach to security prevention and response for its worldwide customer and partner base. SecurityScorecard continues to make the world a safer place by transforming the way companies understand, improve and communicate cybersecurity risk to their boards, employees and vendors. Every organization has the universal right to their trusted and transparent Instant SecurityScorecard rating. For more information, visit securityscorecard.com or connect with us on LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220919005109/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN26.10.2026 11:30:00 CET | Press release
Second limited-edition WHOOP x SR_A collection brings “performance for life” to new WHOOP bands, technical apparel, outerwear, and accessories designed for movement across city and rural environments. WHOOP, the human performance brand, today announced Layer 2 of PROJECT TERRAIN, its multiyear collaboration with British designer Samuel Ross MBE and his design atelier, SR_A. Building on the sold out debut collection launched in March 2026, Layer 2 expands PROJECT TERRAIN to its next season connecting lifestyle and performance for movement, adaptability and zone based training. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026029587/en/ WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN While the first PROJECT TERRAIN collection harnessed dense cities and modern training grounds, Layer 2 explores performance through material, silhouette and tactility. Drawing on the textures, conditions, and flux of the natural wo
Bleeding gums? Don't ignore the warning signs – the first stage of gum disease can be reversed26.10.2026 11:28:00 CET | Press release
Oral-B iO helps you avoid new tooth and gum issues—and if you have existing gum problems, it can resolve them quicker than a manual toothbrush. Gums bleeding when brushing can happen to any of us, and it is easy to ignore. But blood in the sink is a sign that something is not right with your mouth. Bleeding gums often indicate gingivitis, the earliest and most common form of gum disease. The good news: gingivitis can be reversed with proper oral hygiene. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022835650/en/ Oral-B iO Left untreated, gingivitis can progress into periodontitis, a more severe stage of gum disease that can only be managed, not reversed, and can lead to losing teeth over time. Healthy gums matter beyond the mouth, too. Oral health and systemic health are deeply interconnected, with inflammation and bacteria from oral diseases contributing to conditions such as heart disease, diabetes and dementia. "Gums
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 08:00:00 CET | Press release
Clinical and preclinical presentations reflect the company’s ongoing exploration of peripheral neuropathic pain Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greates
Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom